UF startup Myosin Therapeutics, a clinical stage biotechnology company developing innovative therapies for oncology, announced that the first patient has been dosed in its Phase 1/2 STAR-GBM study. The trial is designed to assess safety, tolerability, pharmacokinetics, and preliminary signals of clinical activity with longitudinal imaging in adults with newly diagnosed glioblastoma (GBM). With support from the National Cancer Institute (NCI/NIH), the trial is being conducted in collaboration with the Mayo Clinic across its Minnesota, Florida, and Arizona campuses.
MT-125 is a first-in-class inhibitor of non-muscle myosin II (NMII), designed to disrupt the physical mechanics of tumor cells to induce tumor cell collapse and death through non-redundant mechanisms distinct from any existing therapy.
Read more about Myosin Therapeutics Initiates Phase 1/2 STAR-GBM Trial of MT-125 Targeting Non-Muscle Myosin II in Newly Diagnosed Glioblastoma.
